These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38364701)

  • 1. Genomic characteristics and immune landscape of super multiple primary lung cancer.
    Yang Z; Zhou B; Guo W; Peng Y; Tian H; Xu J; Wang S; Chen X; Hu B; Liu C; Wang Z; Li C; Gao S; He J
    EBioMedicine; 2024 Mar; 101():105019. PubMed ID: 38364701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and immune characteristics of multiple primary lung cancers and lung metastases.
    Yang R; Li P; Wang D; Wang L; Yin J; Yu B; Li M; Wang S; Wang Y
    Thorac Cancer; 2021 Oct; 12(19):2544-2550. PubMed ID: 34510768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and transcriptomic significance of multiple primary lung cancers detected by next-generation sequencing in clinical settings.
    Yao M; Chen H; Chen Z; Wang Y; Shi D; Wu D; Li W; Huang J; Chen G; Zheng Q; Ye Z; Zheng C; Yang Y
    Carcinogenesis; 2024 Jun; 45(6):387-398. PubMed ID: 38693810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and genetic characteristics of early-stage multiple primary and independent primary lung adenocarcinoma patients.
    Li P; Yang R; Wang D; Wang L; Wang S; Liu C; Li J; Li L; Liu C; Tong Y; Wang Y
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e420-e426. PubMed ID: 35098658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
    Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
    Front Immunol; 2020; 11():594212. PubMed ID: 33552051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
    Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
    Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
    Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
    Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.
    Tian H; Wang Y; Yang Z; Chen P; Xu J; Tian Y; Fan T; Xiao C; Bai G; Li L; Zheng B; Li C; He J
    Cancer Gene Ther; 2023 Mar; 30(3):507-520. PubMed ID: 36653483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
    Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
    J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer.
    Guo W; Zhou B; Bie F; Huai Q; Xue X; Guo L; Tan F; Xue Q; Zhao L; Gao S
    Clin Transl Med; 2023 Oct; 13(10):e1453. PubMed ID: 37846760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
    Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
    Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases.
    Li Z; Lv H; Zhang F; Zhu Z; Guo Q; Wang M; Huang C; Guo L; Meng F; Tian Z
    PeerJ; 2024; 12():e16808. PubMed ID: 38313018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple primary lung cancer: A literature review.
    Romaszko AM; Doboszyńska A
    Adv Clin Exp Med; 2018 May; 27(5):725-730. PubMed ID: 29790681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.